Search

Your search keyword '"Vaccines -- Marketing"' showing total 18 results
Start Over Descriptor "Vaccines -- Marketing" Journal pharmabiz
18 results on '"Vaccines -- Marketing"'

1. European Commission grants full marketing authorization to Novavax's Nuvaxovid for prevention of Covid

Subjects
United States. Food and Drug Administration, Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for [...]

Published
2023

2. UK MHRA grants marketing authorization to SK bioscience's Covid-19 vaccine, SKYCovion

Subjects
Biological products industry -- Marketing, Independent regulatory commissions, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, Coalition for Epidemic Preparedness Innovations
Abstract

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, has announced the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

Published
2023

3. EMA committee recommends full marketing authorization for Novavax's Nuvaxovid for prevention of Covid in EU

Subjects
United States. Food and Drug Administration, Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax, Inc., a global company advancing protein-based vaccines with its novel Matrix-M adjuvant, announced that Nuvaxovid (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary [...]

Published
2023

4. EMA committee recommends marketing authorization for use of Moderna's Spikevax in children 6 months to 5 years

Subjects
Moderna Inc. -- Marketing, RNA, Vaccines -- Marketing, Marketing, Coronaviruses, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union. European Commission
Abstract

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a [...]

Published
2022

5. EMA accepts Moderna's conditional marketing authorization filing for its Omicron BA.4/BA.5 targeting bivalent Covid-19 vaccine

Subjects
Moderna Inc. -- Marketing, Biotechnology industry -- Marketing, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, Spikevax Bivalent Zero/Omicron (Vaccine) -- Marketing
Abstract

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency (EMA) has accepted a variation for the evaluation of a 50 ôg [...]

Published
2022

6. CHMP recommends for conversion of Pfizer & BioNTech's Comirnaty conditional marketing authorization to full marketing authorization in EU

Subjects
BioNTech SE -- Marketing, Pfizer Inc. -- Marketing, Biotechnology industry -- Marketing, Drug approval, Vaccines -- Marketing, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) [...]

Published
2022

7. EMA committee recommends conditional marketing authorization for Pfizer & BioNTech's Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine booster

Subjects
BioNTech SE -- Marketing, Pfizer Inc. -- Marketing, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Pfizer Inc. and BioNTech SE announced a 30-ôg booster dose of their Omicron BA.4/BA.5 bivalent-adapted Covid-19 vaccine (Comirnaty Original/Omicron BA.4/BA.5 15/15 ôg) has been recommended for conditional marketing authorization (cMA) [...]

Published
2022

8. CHMP recommends expanded conditional marketing authorization to Novavax Nuvaxovid Covid-19 vaccine in EU as a booster for adults aged 18 and older

Subjects
Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Adults, Vaccines -- Marketing, Marketing, Severe acute respiratory syndrome -- Prevention, Coronaviruses, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, Nuvaxovid (Vaccine) -- Marketing
Abstract

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Nuvaxovid (NVX-CoV2373) Covid-19 vaccine has been recommended for expanded conditional marketing authorization [...]

Published
2022

9. EMA committee recommends conditional marketing authorization to Pfizer & BioNTech's Omicron BA.1-adapted bivalent Covid-19 vaccine booster

Subjects
BioNTech SE -- Marketing, Pfizer Inc. -- Marketing, Biotechnology industry -- Marketing, RNA, Vaccines -- Marketing, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union
Abstract

Pfizer Inc. and BioNTech SE announced a 30-ôg booster dose of their Omicron BA.1 Bivalent Covid-19 vaccine (Comirnaty Original/Omicron BA.1 15/15 ôg) has been recommended for conditional marketing authorization (cMA) [...]

Published
2022

10. EMA committee recommends authorization for use of Moderna's Omicron-targeting bivalent booster, Spikevax

Subjects
Moderna Inc. -- Marketing, Biotechnology industry -- Marketing, RNA, Vaccines -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union. European Commission
Abstract

Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a [...]

Published
2022

11. Takeda to transfer marketing authorization for Spikevax Covid-19 vaccine in Japan to Moderna

Subjects
Moderna Inc. -- Marketing -- International economic relations, Vaccination, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda have announced the transfer of the marketing authorization for Moderna's Covid-19 vaccine Spikevax (mRNA-1273) from Takeda [...]

Published
2022

12. C Com Digital adopts AI-powered marketing strategies to convey diseases and disorders with empathy

Subjects
Advertising agencies, Electronic marketing, Vaccines -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau C Com Digital, a full-service techno digital marketing agency with global footprint, is bringing about a paradigm shift in digital marketing approaches for the pharma sector. The [...]

Published
2021

13. Novavax's Nuvaxovid Covid-19 vaccine receives conditional marketing authorization from European Commission

Subjects
Novavax Inc. -- Marketing, Biotechnology industry -- Marketing, Drug approval, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries, European Union, European Union. European Commission
Abstract

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that the European Commission (EC) has granted Novavax conditional marketing authorization (CMA) for [...]

Published
2021

14. Moderna Covid-19 vaccine, Spikevax manufactured in Korea by Samsung Biologics gets Korean MFDS marketing authorization

Subjects
Contract manufacturing, Drug approval, RNA, Vaccines -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Spikevax, [...]

Published
2021

15. Boehringer Ingelheim launches new porcine parvovirus vaccine, Reprocyc ParvoFLEX in selected countries within EU

Subjects
Boehringer Ingelheim GmbH -- Marketing, Vaccines -- Marketing, Pork industry -- Marketing, Pharmaceutical industry -- Marketing, Pay-per-view television -- Marketing, Drug approval, Swine -- Marketing, Death, Technology, Marketing, Infection, Farms, Fetal death, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

After obtaining the marketing authorization from the European Commission, Boehringer Ingelheim, a research-driven pharmaceutical company, launches Reprocyc ParvoFLEX in selected countries within the EU, a new porcine parvovirus vaccine to [...]

Published
2019

16. Serum Institute ropes in Kareena Kapoor Khan as brand ambassador for Swasth Immunised India campaign

Subjects
Vaccines -- Marketing, Vaccination, Biological products industry -- Marketing, Actors, Physical fitness, Immunization, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau Serum Institute of India, one of the world's largest vaccine manufacturers, has roped in noted actress Kareena Kapoor Khan as the brand ambassador for Swasth Immunised India [...]

Published
2019

17. Indian Immunologicals launches India's first intranasal vaccine for Parvo virus in dogs

Subjects
Vaccines -- Marketing, Vaccination, Dogs, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau Indian Immunologicals Limited (IIL) has launched India's first nasal vaccine against dreaded Parvo virus for dogs branded as Megavac-P Nasal which will protect pups as young as [...]

Published
2017

18. Indian Immunologicals launches India's 1st intranasal vaccine for Parvo virus in Dogs

Subjects
Vaccines -- Marketing, Vaccination, Dogs, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau Indian Immunologicals Limited (IIL) launches India's first nasal vaccine against dreaded Parvo virus for Dogs- Branded as MEGAVAC-P NASAL the vaccine will protect pups as young as [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results